Form PTO-892
U.S. Department of Commerce

Notice of References Cited

Serial Number

O9/756,411

Group Art
Unit
Paper Number

09/756,411

Attachment to
Paper Number

O9/756,411

Lori et al.

U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
*	A	4,708,818 A	11/24/87	Montagnier et al.	435	005.000	
*	В	5,026,687 A	06/25/91	Yarchoan et al.	514	045.000	
*	C	5,110,600 A	05/05/92	Green	424	450.000	
*	D	5,300,059 A	04/05/94	Rubinstein et al.	604	408.000	
*	$\mathbf{E}$	5,521,161 A	05/28/96	Malley et al. (I)	514	045.000	
*	F	5,736,526 A	04/07/98	Malley et al. (II)	514	045.000	
*	G	5,736,527 A	04/07/98	Malley et al. (III)	514	045.000	
*	H	6,046,175 A	04/04/20	Lori et al. (I)	514	045.000	
*	I	6,093,702 A	07/25/00	Malley et al. (IV)	514	045.000	
*	J	6,194,390 B1	02/27/01	Lori et al. (II)	514	045.000	
*	K	6,093,702 A	07/25/00	Malley et al. (V)	514	045.000	

Foreign Patent Documents

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB- CLASS	
*	L	EP 0,206,497 A2	12/30/86	Europe(EPO)	Wellcome Fndtn			
*	M	W O 87/01284 A1	03/12/87	World(WO/PCT)	US Dept. Commerce			

*	R	Gao et al. (I), "Low Levels of Deoxynucleotides in Peripheral Blood
		Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type 1
		Replication,"
		Proc. National Academy Sciences USA, 90, 8925-8928 (October, 1993).

<sup>†</sup> Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

	DATE	page 1 of 6	
L. E. Crane M Cam	03/23/05	¥: Reference not presently	available.
*A copy of this	reference is not bei	ng furnished with this office action.	
(See Manual	of Patent Examinin	g Procedure, Section 707.05(a).)	

Form PTO-892 U.S. Department of Commerce	Serial Number		Attachment to Paper Number
	09/756,411	1623	03312005
Notice of References Cited	APPLICANT(S)		
		Lori et	al.

agents,						
1-342.						
Feorino et al., "Prevention of Activation of HIV-1 by Antiviral Agents in						
OM-10.1 Cells,"						
ives on						
e in Log						
rticular.						
Licastro et al., "Inhibition of Polymerases-α and -ß Completely Blocks						
Cells,"						
Biochemical Biophysical Res. Comm., 132(3), 929-933 (Nov. 15, 1985).						
Busso et al., "Cellular Pharmacology and Anti-HIV Activity of 2',3'-						
Dideoxyguanosine,"						
AIDS Res. Human Retroviruses, 6(9), 1139-1146 (1990).						
R. S. Root-Bernstein(I), "AIDS IS More Than HIV: Part I,"						
Genetic Engineering News, September 1, 1992, pp. 4-6.						
R. S. Root-Bernstein(II), "AIDS IS More Than HIV: Part II,"						
Genetic Engineering News, September 15, 1992, pp. 4-5.						
"Kaposi's Sarcoma and Pneumocystis Pneumonia Among Homosexual Men,"						
al Men,"						
ial Men," ease						

<sup>†</sup> Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

	DATE	page 2 of 6				
L. E. Crane // Com	03/23/05	¥: Reference not presently available.				
*A copy of this reference is not being furnished with this office action.						
(See Manual	of Patent Examinin	g Procedure, Section 707.05(a).)				

Form PTO-892 U.S. Department of Commerce	Serial Number		Attachment to Paper Number
	09/756,411	1623	03312005
Notice of References Cited	APPLICANT(S)		
		Lori et	al.

		Other References (Including Author, 11tle, Date, Pertinent Pages, etc.)					
*	RA <sup>†</sup>	Barre-Sinoussi et al., "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS),"  Science, 220, 868-871 (1983).					
*	SA	Fauci (I), "The Human Immunodeficiency Virus: Infectivity and					
		Mechanisms of Pathogenesis,"					
_	<b>Æ</b> Å	Science, 239, 617-622 (February 1988).					
*	TA	Fauci (II), "Multifactoral Nature of Human Immunodeficiency Virus					
		Disease: Implications for Therapy,"					
		Science, 262, 1011-1018 (November 12, 1993).					
*	UA	Zack et al., "HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular					
		Analysis Reveals a Labile, Latent Viral Structure,"					
		Cell, 61, 213-222 (April 20, 1990).					
*	VA	Bukrinsky et al., "Quiescent T Lymphocytes as an Inducible Virus					
	,	Reservoir in HIV-1 Infection,"					
		Science, 254, 233-237 (October 18, 1991).					
*	<b>XX</b> 7 A						
	VV A	Schnittman et al., "The Reservoir for HIV-1 in Human Peripheral Blood Is					
		a T Cell that Maintains Expression of CD4,"					
		Science, 245, 305-308 (July, 1989).					
*	XA	Fox et al., "Lymphoid Germinal Centers Are Resevoirs of Human					
		Immunodeficiency Virus Type 1 RNA,"					
		Journal of Infectious Diseases, 164, 1051-1057 (December, 1991).					
*	YA	Hirsch et al., "Therapy for Human Immunodeficiency Virus Infection,"					
		New England Journal of Medicine, 328(23), 1686-1695 (June 10, 1993).					
لبا		of publication data is unavailable. Issue Number information is resulted as because the fall with the					

<sup>†</sup> Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER	DATE	page 3 of 6
L. E. Crane	03/23/05	¥: Reference not presently available.
		ng furnished with this office action.
(See Manual	of Patent Examinin	g Procedure, Section 707.05(a).)

Form PTO-892 U.S. Department of Commerce	Serial Number		Attachment to Paper Number	
	09/756,411	1623	03312005	
Notice of References Cited	APPLICANT(S)			
·		Lori et	al.	

ZA <sup>†</sup>	Pauwels et al., "Rapid and Automated Tetrazolium-Based Colorimetric			
	Assay for the Detection of Anti-HIV Compounds,"			
	Journal of Virological Methods, 20, 309-321 (1988).			
RB	Yarchoan et al., "Clinical Pharmacology of 3'-Azido-2', 3'-			
	dideoxythymidine (Zidovudine) and Related Dideoxynucleosides,"			
	New England Journal of Medicine, 321(11), 726-738 (September 14, 1989).			
SB†	Chow et al., "Use of Evolutionary Limitations of HIV-1 Multidrug			
	Resistance to Optimize Therapy,"			
	Nature, 361, 650-654 (1993).			
TB	Lori et al.(III), "Hydroxyurea as an Inhibitor of Human Immunodeficiency			
	Virus-Type 1 Replication,"			
	Science, 266, 801-805 (November 4, 1994).			
UB†	Karlsson et al., "Hydroxyurea Increases the Phosphorylation of 3'-			
	fluorothymidine and 3'-Azidothymidine in CEM Cells,"			
	European Journal of Biochemistry, 186, 689-694 (1989).			
VB <sup>†</sup>	Marquez et al., "Acid-Stable 2'-Fluoro Purine Dideoxynucleosides as			
	Active Agents Against HIV,"			
	Journal of Medicinal Chemistry, 33(3), 978-985 (1990).			
WB <sup>†</sup>	Snyder et al. (II), "The Accumulation of DNA Breaks Due to Incision;			
	Comparative Studies with Various Inhibitors," Ch. 2 in <u>DNA Repai</u> et al. <u>r and</u>			
	Its Inhibition, Nucleic Acids Symposium Series No. 13, Collins et al. eds., IRL			
	Press, Oxford, England, 1984, pp. 13-33.			
	RB SB <sup>†</sup> TB UB <sup>†</sup>			

<sup>†</sup> Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER /	DATE	page 4 of 6
L. E. Crane // / Cam	03/23/05	¥: Reference not presently available.
ii copy of this	reference is not our	ng furnished with this office action. g Procedure, Section 707.05(a).)

Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number
	09/756,411	1623	03312005
Notice of References Cited	APPLICANT(S)		<del></del>
		Lori et	al.

		determines (including Author, Title, Date, Teltinent Tages, etc.)
*	XB	Vila et al., "Absence of Viral Rebound After Treatment of HIV-Infected
		Patients with Didanosine [ddI] and Hydroxycarbamide [aka Hydroxyurea],"
		Lancet, 350(9078), 635-636 (August 30, 1997).
*	YB	Schoofs, "The Berlin Patient,"
		The New York Times Magazine, pp. 32-35, June 21, 1998.
*	$\mathbf{Z}\mathbf{B}^{\dagger}$	Balzarini, J., "Effect of Antimetabolite Drugs of Nucleotide Metabolism on
		the Anti-Human Immunodeficiency Virus Activity of Nucleoside Reverse
		Transcriptase Inhibitors,"
		Pharmacology and Therapeutics, 87(2-3), 175-187 (2000).††
*	$\mathbf{RC}^{\dagger}$	Gao et al. (II), "Enhancement by Hydroxyurea of the Anti-Human
		Immunodeficiency Virus Type 1 Potency of 2'-β-Fluoro-2',3'-
		dideoxyadenosine in Peripheral Blood Mononuclear Cells,"
		Biochemical Pharmacology, 50(2), 274-276 (1995).††
*	SC <sup>†</sup>	Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically
*	SC†	
*	SC <sup>†</sup>	Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically
*		Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine,"
		Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine," Molecular Pharmacology, 37, 590-596 (1990).
		Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine," Molecular Pharmacology, 37, 590-596 (1990).  Hitchcock et al., "Biochemical Pharmacology of 2'-Fluoro-2',3'-
		Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine," <i>Molecular Pharmacology</i> , 37, 590-596 (1990).  Hitchcock et al., "Biochemical Pharmacology of 2'-Fluoro-2',3'-dideoxyarabinosyladenine, an Inhibitor of HIV with Improved Metabolic and
		Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine," Molecular Pharmacology, 37, 590-596 (1990).  Hitchcock et al., "Biochemical Pharmacology of 2'-Fluoro-2',3'-dideoxyarabinosyladenine, an Inhibitor of HIV with Improved Metabolic and Chemical Stability over 2',3'-Dideoxyadenosine," Antiviral Chemistry & Chemotherapy, 1, 319-327 (1990).
*	TC†	Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine," Molecular Pharmacology, 37, 590-596 (1990).  Hitchcock et al., "Biochemical Pharmacology of 2'-Fluoro-2',3'-dideoxyarabinosyladenine, an Inhibitor of HIV with Improved Metabolic and Chemical Stability over 2',3'-Dideoxyadenosine," Antiviral Chemistry & Chemotherapy, 1, 319-327 (1990).
*	TC†	Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine," Molecular Pharmacology, 37, 590-596 (1990).  Hitchcock et al., "Biochemical Pharmacology of 2'-Fluoro-2',3'-dideoxyarabinosyladenine, an Inhibitor of HIV with Improved Metabolic and Chemical Stability over 2',3'-Dideoxyadenosine," Antiviral Chemistry & Chemotherapy, 1, 319-327 (1990).  Gao et al. (III), "Differential Phosphorylation of Azidothymidine,
*	TC†	Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine," Molecular Pharmacology, 37, 590-596 (1990).  Hitchcock et al., "Biochemical Pharmacology of 2'-Fluoro-2',3'-dideoxyarabinosyladenine, an Inhibitor of HIV with Improved Metabolic and Chemical Stability over 2',3'-Dideoxyadenosine," Antiviral Chemistry & Chemotherapy, 1, 319-327 (1990).  Gao et al. (III), "Differential Phosphorylation of Azidothymidine, Dideoxycytidine, and Dideoxyinosine in Resting and Activated Peripheral

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Copy kindly supplied by Applicant.

EXAMINER ()	DATE	page 5 of 6			
L. E. Crane \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	03/23/05	¥: Reference not presently available.			
*A copy of this reference is not being furnished with this office action.					
(See Manual	of Patent Examinin	g Procedure, Section 707.05(a).)			

Form PTO-892 U.S. Department of Commerce	Serial Number		Attachment to Paper Number
	09/756,411	1623	03312005
Notice of References Cited	APPLICANT(S)		
		Lori et	al.

*	VC <sup>†</sup>	Sumpter et al., "In Vivo Examination of Hydroxyurea and the Novel Ribonucleotide Reductase Inhibitors Trimidox and Didox in Combination with the Reverse Transcriptase Inhibitor Abacavir: Suppression of Retrovirus-induced Immunodeficiency,"  Antiviral Research, 62, 111-120 (2004).††
*	WC	Palmer et al., "Hydroxyurea Enhances the Activities of Didanosine, 9-[2-(Phosphonylmethoxy)ethyl]adenine, and 9-[2-(Phosphonylmethoxy)propyl]adenine Against Drug-Susceptible and Drug-Resistant Human Immunodeficiency Isolates,"  Antimicrobial Agents and Chemotherapy, 43(8), 2046-2050 (Aug., 1999).††
	XC	Parker et al., "Mitochondrial Toxicity of Antiviral Nucleoside Analogs,"  The Journal of NIH Research, 6, 57-61 (March, 1994).
	YC	Rajs et al., "Sudden Unexpected Death as a Consequence of Indinavir-Induced Nephropathy: A Case Report,"  Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS),  108(9), 581-583 (September, 2000).

<sup>&</sup>lt;sup>†</sup> Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER
L. E. Crane

O 3/23/05

The page 6 of 6

Where the page 6 of 6

Figure 1 and 1 and 2 and 2 and 3 an

<sup>††</sup> Copy kindly supplied by Applicant.

# Notice of References Cited

Application/Control No. 09/756,411

Applicant(s)/Patent Under Reexamination LORI ET AL.

Examiner

L. E. Crane

Art Unit 1623

Page 1 of 9

# U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	А	US-4,708,818 A	11-1987	Montagnier et al.	435/5
*	В	US-5,026,687 A	06-1991	Yarchoan et al.	514/45
*	С	US-5,110,600 A	05-1992	Green, Melvin H.	424/450
*	D	US-5,300,059 A	04-1994	Rubinstein et al.	604/408
*	Е	US-5,521,161 A	05-1996	Malley et al.	514/45
*	F	US-5,736,526 A	04-1998	Malley et al.	514/45
*	G	US-5,736,527 A	04-1998	Malley et al.	514/45
*	Н	US-6,046,175 A	04-2000	Lori et al.	514/45
*	1	US-6,093,702 A	07-2000	Malley et al.	514/45
*	J	US-6,194,390 B1	02-2001	Lori et al.	514/45
	к	US-			
	L	US-			
	М	US-		·	

# FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
*	N	(L) EP 0,206,497 A2	12-1986	Europe (EPO)	Wellcome Foundation	
*	0	(M) WO87/01284 A1	03-1987	World(WO/PCT)	US Dept. of Commerce	
	Ρ					
	ø					
	R					
	s					
	Т		,			

## **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
*	U	[R] Gao et al. (I), "Low Levels of Deoxynucleotides in Peripheral Blood Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type 1 Replication," Proc. National Academy Sciences USA, 90, 8925-8928 (October, 1993).
*	v	(S) Biochemicals/Organic Compounds for Research and Diagnostic Reagents, Sigma Chemical Co. (catalog), St. Louis, MO, 1992, pp. 321, 341-342.
*	w	(T) Feorino et al., "Prevention of Activation of HIV-1 by Antiviral Agents in OM-10.1 Cells," Antiviral Chemistry & Chemotherapy, 4(1), 55-63 (1993).
*	х	(U) Snyder et al. (I), "Effects of Hydroxyurea and Thymidine Derivatives on the Uptake and Metabolism of Deoxycytidine and Arabinosylcytosine in Log Phase and Contact-Inhibited Human Fibroblasts," Molecular Pharmacology, 28(6), 574-580 (1985); see p. 578

# Application/Control No. O9/756,411 Applicant(s)/Patent Under Reexamination LORI ET AL. Examiner L. E. Crane Applicant(s)/Patent Under Reexamination LORI ET AL. Page 2 of 9

# **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			`
	E	US-			
	F	US-			
	G	US-			
	Н	US-		·	
	1	US-			
	J	US-			
	κ	US-			
	L	US-			
	М	US-			

## FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name		Classification
	N						
	0						···
	Р						
	Q						
	R						
	S					-	
	Т						

## **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
*	Ü	(V) Licastro et al., "Inhibition of Polymerases-alpha and -beta Completely Blocks DNA Repair Induced by UV Irradiation in Cultured Mouse Neuronal Cells,"  Biochemical Biophysical Res. Comm., 132(3), 929-933 (Nov. 15, 1985).
*	V	(W) Busso et al., "Cellular Pharmacology and Anti-HIV Activity of 2',3'-Dideoxyguanosine," AIDS Res. Human Retroviruses, 6(9), 1139-1146 (1990).
*	w	(X) R. S. Root-Bernstein (I), "AIDS IS More Than HIV: Part I," Genetic Engineering News, September 1, 1992, pp. 4-6.
*	х	(Y) R. S. Root-Bernstein (II), "AIDS IS More Than HIV: Part II," Genetic Engineering News, September 15, 1992, pp. 4-5.

# Notice of References Cited Application/Control No. O9/756,411 Examiner L. E. Crane Applicant(s)/Patent Under Reexamination LORI ET AL. Page 3 of 9

# U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	- Name	Classification
	А	US-			
	В	US-	,		
	С	US-			
	D	US-			
	Ε	US-			
	F	US-			
	G	US-			
	Н	US-			
	1	US-			
	J	US-			
	к	US-			
	L	US-			
	М	US-			

### **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	Z					
	0			-		
	Р					
	a					
	R					
	s					
	Т					

# **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
*	U	(Z) "Kaposi's Sarcoma and Pneumocystis Pneumonia Among Homosexual Men," Morbidity Mortality Weekly Rept., Vol. 30(25), Centers for Disease Control, July 3, 1981, pp. 305-308.
*	٧	(RA) Barre-Sinoussi et al., "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)," Science, 220, 868-871 (1983).
*	w	(SA) Fauci (I), "The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis," Science, 239, 617-622 (February 1988).
*	х	(TA) Fauci (II), "Multifactoral Nature of Human Immunodeficiency Virus Disease: Implications for Therapy," Science, 262, 1011-1018 (November 12, 1993).

# Notice of References Cited Application/Control No. O9/756,411 Examiner L. E. Crane Applicant(s)/Patent Under Reexamination LORI ET AL. Art Unit 1623 Page 4 of 9

U.S. PATENT DOCUMENTS

*	-	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	Е	US-		,	
	F	US-			
	G	US-			
	Η,	US-			
	ı	US-			
	J	US-			
	κ	US-			
	L	US-			
	М	US-			

### FOREIGN PATENT DOCUMENTS

	FOREIGN FATERI DOCUMENTS					
*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Ø					
	R					
	S					
	Т					

# **NON-PATENT DOCUMENTS**

	т —	
*	L.	Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
*	U	(UA) Zack et al., "HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure," Cell, 61, 213-222 (April 20, 1990).
*	V	(VA) Bukrinsky et al., "Quiescent T Lymphocytes as an Inducible Virus Reservoir in HIV-1 Infection," Science, 254, 233-237 (October 18, 1991).
*	W.	(WA) Schnittman et al., "The Reservoir for HIV-1 in Human Peripheral Blood Is a T Cell that Maintains Expression of CD4," Science, 245, 305-308 (July, 1989).
*	х	(XA) Fox et al., "Lymphoid Germinal Centers Are Resevoirs of Human Immunodeficiency Virus Type 1 RNA," Journal of Infectious Diseases, 164, 1051-1057 (December, 1991).

# Notice of References Cited Application/Control No. O9/756,411 Examiner L. E. Crane Applicant(s)/Patent Under Reexamination LORI ET AL. Page 5 of 9

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-		7	
	С	US-			
	D	US-			
	Е	US-			
	F	US-			
	G	US-			
	Н	US-			
	ı	US-			
	J	US-			
	κ	US-		,	
	L	US-			
	м	US-			

### **FOREIGN PATENT DOCUMENTS**

	TOTALIST TYTER BOOMERTO					
*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	s					
	Т					

# **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
*	U	(YA) Hirsch et al., "Therapy for Human Immunodeficiency Virus Infection," New England Journal of Medicine, 328(23), 1686-1695 (June 10, 1993).
*	V	(ZA) Pauwels et al., "Rapid and Automated Tetrazolium-Based Colorimetric Assay for the Detection of Anti-HIV Compounds," Journal of Virological Methods, 20, 309-321 (1988).
*	w	(RB) Yarchoan et al., "Clinical Pharmacology of 3'-Azido-2', 3'-dideoxythymidine (Zidovudine) and Related Dideoxynucleosides," New England Journal of Medicine, 321(11), 726-738 (September 14, 1989).
*	х	(SB) Chow et al., "Use of Evolutionary Limitations of HIV-1 Multidrug Resistance to Optimize Therapy," Nature, 361, 650-654 (1993).

# Notice of References Cited Application/Control No. 09/756,411 Examiner L. E. Crane Applicant(s)/Patent Under Reexamination LORI ET AL. Art Unit 1623 Page 6 of 9

# U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	А	US-			
	В	US-			
	С	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	н	US-			
	ı	US-			
	J	US-			
	к	US-			
	L	US-			
	М	US-			

### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	s					
	Т					

## **NON-PATENT DOCUMENTS**

		NON-PATENT DOCUMENTS
*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
*	U	(TB) Lori et al.(III), "Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication," Science, 266, 801-805 (November 4, 1994).
*	v	(UB) Karlsson et al., "Hydroxyurea Increases the Phosphorylation of 3'-fluorothymidine and 3'-Azidothymidine in CEM Cells," European Journal of Biochemistry, 186, 689-694 (1989).
*	w	(VB) Marquez et al., "Acid-Stable 2'-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV," Journal of Medicinal Chemistry, 33(3), 978-985 (1990).
*	х	(WB) Snyder et al. (II), "The Accumulation of DNA Breaks Due to Incision; Comparative Studies with Various Inhibitors," Ch. 2 in DNA Repair and Its Inhibition, Nucleic Acids Symposium Series No. 13, Collins et al. eds., IRL Press, Oxford, GB, 1984, p 13-33

# Notice of References Cited Application/Control No. O9/756,411 Examiner L. E. Crane Applicant(s)/Patent Under Reexamination LORI ET AL. Art Unit 1623 Page 7 of 9

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	А	US-			
	В	US-			
	С	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-		·	112
	Н	US-			
	1	US-			
	J	US-			***************************************
	К	US-			-
	L	US-			
	М	US-			

## **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р			V-1		
	Q			****		~
	R					
	s					
	Т					

# **NON-PATENT DOCUMENTS**

	NOTE ATENT BOOMENTO				
*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)			
*	U	(XB) Vila et al., "Absence of Viral Rebound After Treatment of HIV-Infected Patients with Didanosine [ddl] and Hydroxycarbamide [aka Hydroxyurea]," Lancet, 350(9078), 635-636 (August 30, 1997).			
*	V	(YB) Schoofs, "The Berlin Patient," The New York Times Magazine, pp. 32-35, June 21, 1998.			
*	w	(ZB) Balzarini, J., "Effect of Antimetabolite Drugs of Nucleotide Metabolism on the Anti-Human Immunodeficiency Virus Activity of Nucleoside Reverse Transcriptase Inhibitors," Pharmacology and Therapeutics, 87(2-3), 175-187 (2000).			
*	х	(RC) Gao et al. (II), "Enhancement by Hydroxyurea of the Anti-Human Immunodeficiency Virus Type 1 Potency of 2'-beta-Fluoro-2',3'-dideoxyadenosine in Peripheral Blood Mononuclear Cells," Biochemical Pharmacology, 50(2), 274-276 (1995).			

# Notice of References Cited Application/Control No. O9/756,411 Examiner L. E. Crane Applicant(s)/Patent Under Reexamination LORI ET AL. Page 8 of 9

U.S. PATENT DOCUMENTS

			·	U.S. PATENT DOCUMENTS	
*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-		·	•
	Е	US-			
	F	US-			*
	G	US-			
	Η	US-			
	-	US-			
	J	US-			
	К	US-			
	Г	US-			
	М	US-			

## **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					·
	a					
	R					
	s					
	Т					

# **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
*	U	(SC) Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine,"  Molecular Pharmacology, 37, 590-596 (1990).
*	V	(TC) Hitchcock et al., "Biochemical Pharmacology of 2'-Fluoro-2',3'-dideoxyarabinosyladenine, an Inhibitor of HIV with Improved Metabolic and Chemical Stability over 2',3'-Dideoxyadenosine," Antiviral Chemistry & Chemotherapy, 1, 319-327 (1990).
*	w	(UC) Gao et al. (III), "Differential Phosphorylation of Azidothymidine, Dideoxycytidine, and Dideoxyinosine in Resting and Activated Peripheral Blood Mononuclear Cells,"  Journal of Clinical Investigations, 91(5), 2326-2333 (May, 1993).
*	х	(VC) Sumpter et al., "In Vivo Examination of Hydroxyurea and the Novel Ribonucleotide Reductase Inhibitors Trimidox and Didox in Combination with Abacavir. Suppression of Retrovirus-induced Immunodeficiency," Antiviral Research, 62, 111-120 (2004).

### Application/Control No. Applicant(s)/Patent Under Reexamination 09/756,411 LORI ET AL. Notice of References Cited Art Unit Examiner Page 9 of 9 L. E. Crane 1623 U.S. PATENT DOCUMENTS **Document Number** Date Name Classification Country Code-Number-Kind Code MM-YYYY US-Α US-В US-Ç US-D US-Ε F US-US-G USн UŞ-UŞ-J US-Κ US-L US-**FOREIGN PATENT DOCUMENTS Document Number** Date Country Name Classification Country Code-Number-Kind Code MM-YYYY Ν 0 Р Q R S Т **NON-PATENT DOCUMENTS** Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages) (WC) Palmer et al., "Hydroxyurea Enhances the Activities of [ddl], 9-[2-(Phosphonylmethoxy)ethyl]adenine, and U 9-[2-(Phosphonylmethoxy)propyl]adenine Against ... [HIV] Isolates," Antimicrobial Agents and Chemotherapy, 43(8), 2046-2050 (Aug., 1999). (XC) Parker et al., "Mitochondrial Toxicity of Antiviral Nucleoside Analogs," The Journal of NIH Research, 6, 57-61 (March, 1994).

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

W

Pathologica,

Microbiologica et Immunologica Scandinavica (APMIS), 108(9), 581-583 (September, 2000).

(YC) Rajs et al., "Sudden Unexpected Death as a Consequence of Indinavir-Induced Nephropathy: A Case Report," Acta